This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Stopping a cancer cell from dividing does not necessarily make it harmless. Chemotherapy can leave behind living, senescent cells. These 'zombie' cells can release inflammatory signals, helping tumors resist treatment. Drugs that eliminate these lingering cells could help, but they can also harm other cells.

The problem researchers needed to address is that the enzyme commonly used to identify senescent cells also works in some non-senescent tissues, creating a risk of unwanted drug activation. And although light can control where a drug activates, using light alone could act on any cell within the illuminated area. Could a sequential light–enzyme switch combination improve selective targeting?

Mengyang Chang and colleagues at institutions including China's Eastern Institute of Technology and Xinqiao Hospital developed experimental drugs with two molecular locks that are designed to be opened with the two keys: light and an enzyme. In laboratory tests, the combination made the drugs more selective about which cancer cells they killed. The findings are published in the journal Advanced Science.

The researchers paired illumination control with beta-galactosidase, an enzyme whose activity often rises in senescent cells. It can remove a sugar-based covering attached to a drug, releasing the active ingredient. But the enzyme also works in cells that are not senescent, making it an imperfect key on its own.

The new design makes the two triggers work in sequence.

Source link